Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_David Jackson_2024
VIEWPOINTS

SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study

Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024

Read more

VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more

Post Conference Highlights E-Brain OncoVision Connecting the Dots in Cancer Care
EVENTS

Post Conference Highlights: E-Brain OncoVision: Connecting the Dots in Cancer Care

Riveting, insightful, and highly engaging, the two-day event by Ingenious e-brain remained a topic of discussion in the biopharma and healthcare community. PharmaShots as the official media partner had the opportunity to witness the first-ever metaverse-based virtual conference with distinguished keynote speakers from reputed biopharma companies, sharing insights on the present and the future of…
March 12, 2024

Read more

VIEWPOINTS_Susan Pandya_2024
VIEWPOINTS

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Shots:  In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile  While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma  With a fast-track designation and breakthrough therapy…
March 7, 2024

Read more

VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024
VIEWPOINTS

Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots

Shots:  G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis  Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data  Philip further goes ahead to share details on VTAMA’s ongoing study…
February 29, 2024

Read more

Reuters Events Pharma USA 2024
EVENTS

Reuters Events: Pharma USA 2024

Accelerate patient value. Pioneer healthcare’s transformation.  Healthcare reforms are finally paving the way to affordable access to medicines, yet this progress threatens the development of future life-saving therapies. The moment is now to prove ourselves as a trusted industry ally and the ultimate safe harbor for patients.  The key? Delivering aligned value to HCPs, patients, payers and…
February 28, 2024

Read more

ThoughtSpot_Saurabh Chaubey8
THOUGHTSPOT

6 Widely Used Content Marketing Formats by Biopharma Companies

Shots:  Have you ever wondered what content formats leading biopharma companies have been using that receive wonderful responses and wholesome reviews? With PharmaShots, let’s navigate the trending content formats that biopharma companies have been exceedingly using  In the data-driven world regulated by social media, it is necessary to have a strong media presence. For companies…
February 14, 2024

Read more

VIEWPOINTS_Anjay Rastogi_2024
VIEWPOINTS

AstraZeneca at ASN 2023: Anjay Rastogi in a Stimulating Conversation with PharmaShots

Shots: Anjay Rastogi, Professor, and Clinical Chief of Nephrology at UCLA, in an insightful conversation with PharmaShots, shares the highlights of AstraZeneca’s presentation at the American Society of Nephrology At ASN 2023, AstraZeneca shares the analysis from the ZORA study, which is a global RWE program that describes the risk of progression to end-stage kidney…
February 12, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Andrew Menzies-Gow Highlights Data from the MANDARA Study

Shots:  Andrew Menzies-Gow, in a stimulating conversation with PharmaShots, shares the insights from the Phase III MANDARA study that evaluates Fasenra (benralizumab) vs. mepolizumab for patients with relapsing or refractory EGPA  Five out of the 18 abstracts presented by AstraZeneca at ACR were from the MANDARA study. Apart from the positive endpoints of the MANDARA…
February 6, 2024

Read more

VIEWPOINTS_Micki Hultquist_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots:  AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines  Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE)  The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024

Read more

Load more